Sustained-release and instant-release verapamil in treatment of angina pectoris.

Abstract

The efficacy of a sustained-release preparation of verapamil (verapamil-SR) has been compared with that of a conventional instant-release formulation (verapamil-IR) in 10 patients with stable angina pectoris treated for 3 weeks with both preparations. The diurnal serum concentrations of verapamil and norverapamil did not differ significantly during treatment with verapamil-IR 120 mg t.i.d. and verapamil-SR 360 mg once daily, but verapamil-SR 240 mg produced significantly lower serum concentrations. The differences did not affect the exercise capacity or the occurrence of ST-segment depression during maximal exercise. Verapamil-SR was well tolerated. A multiple instant-release dosage regime can now be replaced by once daily administration of the sustained-release preparation.

• Authors: C M Jespersen, N A Klitgaard, H Nielsen, J F Hansen
• Journal: European journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 36 Issue 6 Pg. 625-7 ( 1989) ISSN: 0031-6970 [Print] Germany
• PMID: 2776821 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Delayed-Action Preparations
• norverapamil
• Verapamil

Topics

• Angina Pectoris (drug therapy)
• Delayed-Action Preparations
• Double-Blind Method
• Electrocardiography
• Exercise Test
• Female
• Hemodynamics
• Humans
• Male
• Verapamil (administration & dosage, analogs & derivatives, blood, therapeutic use)